Zheng M - Search Results

1

CD147 reinforces [Ca2+]i oscillations and promotes oncogenic progression in hepatocellular carcinoma.

Tang J, Guo YS, Yu XL, Huang W, Zheng M, Zhou YH, Nan G, Wang JC, Yang HJ, Yu JM, Jiang JL, Chen ZN. Tang J, et al. Among authors: zheng m. Oncotarget. 2015 Oct 27;6(33):34831-45. doi: 10.18632/oncotarget.5225. Oncotarget. 2015. PMID: 26498680 Free PMC article.

2

[Highly expressed CD147 on CD4⁺ tumor infiltrating lymphocytes promotes the progress of breast cancer].

Zheng M, Zhang X, Guo H, Fan C, Chen Z, Zhu P. Zheng M, et al. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015 Jul;31(7):961-4. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015. PMID: 26146069 Chinese.

3

RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression.

Liu ZY, Zheng M, Li YM, Fan XY, Wang JC, Li ZC, Yang HJ, Yu JM, Cui J, Jiang JL, Tang J, Chen ZN. Liu ZY, et al. Among authors: zheng m. Theranostics. 2019 Jun 2;9(12):3659-3673. doi: 10.7150/thno.32126. eCollection 2019. Theranostics. 2019. PMID: 31281505 Free PMC article.

4

CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM/ATR/p53 and affects prognosis in pancreatic cancer.

Zhou Y, Zheng M, Liu Z, Yang H, Zhu P, Jiang JL, Tang J, Chen ZN. Zhou Y, et al. Among authors: zheng m. Biochem Biophys Res Commun. 2020 Jul 12;528(1):62-70. doi: 10.1016/j.bbrc.2020.05.005. Epub 2020 May 23. Biochem Biophys Res Commun. 2020. PMID: 32456796

5

High GINS2 transcript level predicts poor prognosis and correlates with high histological grade and endocrine therapy resistance through mammary cancer stem cells in breast cancer patients.

Zheng M, Zhou Y, Yang X, Tang J, Wei D, Zhang Y, Jiang JL, Chen ZN, Zhu P. Zheng M, et al. Breast Cancer Res Treat. 2014 Nov;148(2):423-36. doi: 10.1007/s10549-014-3172-7. Epub 2014 Oct 28. Breast Cancer Res Treat. 2014. PMID: 25348432

6

Prognostic Landscape of Tumor-Infiltrating T and B Cells in Human Cancer.

Zheng M, Li YM, Liu ZY, Zhang X, Zhou Y, Jiang JL, Zhu P, Yang XM, Tang J, Chen ZN. Zheng M, et al. Front Immunol. 2022 Jan 4;12:731329. doi: 10.3389/fimmu.2021.731329. eCollection 2021. Front Immunol. 2022. PMID: 35069521 Free PMC article.

7

TCR repertoire and CDR3 motif analyses depict the role of αβ T cells in Ankylosing spondylitis.

Zheng M, Zhang X, Zhou Y, Tang J, Han Q, Zhang Y, Ni Q, Chen G, Jia Q, Yu H, Liu S, Robins E, Jiang NJ, Wan Y, Li QJ, Chen ZN, Zhu P. Zheng M, et al. EBioMedicine. 2019 Sep;47:414-426. doi: 10.1016/j.ebiom.2019.07.032. Epub 2019 Aug 30. EBioMedicine. 2019. PMID: 31477563 Free PMC article.

8

Functional defects in CD4⁺ CD25^high FoxP3⁺ regulatory cells in ankylosing spondylitis.

Guo H, Zheng M, Zhang K, Yang F, Zhang X, Han Q, Chen ZN, Zhu P. Guo H, et al. Among authors: zheng m. Sci Rep. 2016 Nov 30;6:37559. doi: 10.1038/srep37559. Sci Rep. 2016. PMID: 27901054 Free PMC article.

9

Conversion of effector CD4⁺ T cells to a CD8⁺ MHC II-recognizing lineage.

Robins E, Zheng M, Ni Q, Liu S, Liang C, Zhang B, Guo J, Zhuang Y, He YW, Zhu P, Wan Y, Li QJ. Robins E, et al. Among authors: zheng m. Cell Mol Immunol. 2021 Jan;18(1):150-161. doi: 10.1038/s41423-019-0347-5. Epub 2020 Feb 17. Cell Mol Immunol. 2021. PMID: 32066854 Free PMC article.

10

Dose-Dependent Effect of Tumor Mutation Burden on Cancer Prognosis Following Immune Checkpoint Blockade: Causal Implications.

Zheng M. Zheng M. Front Immunol. 2022 Jun 3;13:853300. doi: 10.3389/fimmu.2022.853300. eCollection 2022. Front Immunol. 2022. PMID: 35720282 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,482 results

Search Page

Filters